news
UK ATMP clinical trials report 2022 published
T cells were revealed as the most commonly investigated cell type continuing to increase, found CGT Catapult's 2022 UK ATMP clinical trials report.
List view / Grid view
Cell and Gene Therapy Catapult
news
UK cell and gene therapy manufacturing challenge ends in success
In a £1.3 million collaborative project Symbiosis and the Cell and Gene Therapy (CGT) Catapult reduced viral vector manufacturing times by more than 25 percent.
article
Vaccine innovation in the UK: SMEs and national capabilities
The UK Government is supporting the development of COVID-19 vaccines, including two innovative UK vaccine candidates. In this article, we describe the history of these candidates and introduce innovative small and medium enterprises (SMEs) and national capabilities that are working to combat the current pandemic and improve the UK’s vaccine…
news
UK government invests £100 million into COVID-19 vaccine manufacturing
The UK government has committed £100 million to establish a centre to scale up COVID-19 vaccine and gene therapy manufacturing.
news
UK accounts for 12 percent of global cell and gene therapy clinical trials
New research has found that the cell and gene therapy clinical environment in the UK has encouraged commercial sponsorship from around the world.
news
Investment in UK cell and gene therapy manufacturing set to continue
An additional 6,000m2 of cell and gene therapy manufacturing space is expected to become available within the next 12 months, according to new data.
news
Positive interim review in ongoing AML WT1 T cell clinical trial
14 April 2016 | By Victoria White, Digital Content Producer
The Cell and Gene Therapy Catapult has announced a positive interim review of a Phase I/II trial using WT1-TCR t-cell therapy to target acute myeloid leukaemia...
